Compare Gigacloud Technology Inc (GCT) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Natera Inc. Common Stock — how do they compare? Gigacloud Technology Inc trades at $57.41 (market cap $2.06B), while Natera Inc. Common Stock trades at $396.58 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 27.7× Gigacloud Technology Inc's market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, Natera Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 20 Days and Natera Inc. Common Stock for 0 Days on average.
| GCT | NTRA | |
|---|---|---|
Market Cap | $2.06B | $57.03B |
Volume | 820,423 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $57.75 | $425.64 |
52-Week Low | $25.46 | $179.42 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $2.19B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.03, down 1.23% with a bullish technical outlook from moving averages but bearish oscillators. The company shows strong fundamentals with consistent earnings beats, 10.65% net margin, and 32.34% ROE. Revenue grew to $1.29B in 2025 with positive cash flow of $120.10M. Recent news highlights institutional interest and European expansion driving growth.
The stock presents value with a 13.75 P/E ratio but faces technical overbought signals and insider selling. Analyst consensus is bullish with $32.50 price target, though current price exceeds this. Key risks include market volatility and execution challenges in international expansion.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
